NZ337730A - use of an oligosaccharide hapten- carrier conjugate for immunizing against a bacterial or viral pathogen by administering - Google Patents

use of an oligosaccharide hapten- carrier conjugate for immunizing against a bacterial or viral pathogen by administering

Info

Publication number
NZ337730A
NZ337730A NZ337730A NZ33773096A NZ337730A NZ 337730 A NZ337730 A NZ 337730A NZ 337730 A NZ337730 A NZ 337730A NZ 33773096 A NZ33773096 A NZ 33773096A NZ 337730 A NZ337730 A NZ 337730A
Authority
NZ
New Zealand
Prior art keywords
bacterial
administering
oligosaccharide
viral pathogen
carrier conjugate
Prior art date
Application number
NZ337730A
Inventor
Andrew J Malcolm
Original Assignee
Alberta Res Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/477,497 external-priority patent/US5866132A/en
Priority claimed from US08/482,626 external-priority patent/US5695768A/en
Priority claimed from CA002153730A external-priority patent/CA2153730A1/en
Priority claimed from CA002153733A external-priority patent/CA2153733A1/en
Application filed by Alberta Res Council filed Critical Alberta Res Council
Priority claimed from NZ309713A external-priority patent/NZ309713A/en
Publication of NZ337730A publication Critical patent/NZ337730A/en

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A conjugate having at least one oligosaccharide hapten having a multiple of repeat subunits and retaining at least one immunogenic epitope and a carrier which elicits a thymus dependent immune response in a subject is used in the manufacture of a medicament for providing an immune response against bacterial or viral pathogens in a mammal in need of such treatment. The oligosaccharide can from S. pneumoniae serotype 8 and the mammal can be a neonate.
NZ337730A 1995-06-07 1996-06-06 use of an oligosaccharide hapten- carrier conjugate for immunizing against a bacterial or viral pathogen by administering NZ337730A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/477,497 US5866132A (en) 1995-06-07 1995-06-07 Immunogenic oligosaccharide compositions
US08/482,626 US5695768A (en) 1995-06-07 1995-06-07 Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides
CA002153730A CA2153730A1 (en) 1995-07-12 1995-07-12 Immunostimulating activity of streptococcus pneumoniae serotype 8 oligosaccharides
CA002153733A CA2153733A1 (en) 1995-07-12 1995-07-12 Immunogenic oligosaccharide compositions
NZ309713A NZ309713A (en) 1995-06-07 1996-06-06 Oligosaccharides of S pneumoniae serotype 8 and their use in a vaccine

Publications (1)

Publication Number Publication Date
NZ337730A true NZ337730A (en) 2001-01-26

Family

ID=27508580

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ337730A NZ337730A (en) 1995-06-07 1996-06-06 use of an oligosaccharide hapten- carrier conjugate for immunizing against a bacterial or viral pathogen by administering

Country Status (1)

Country Link
NZ (1) NZ337730A (en)

Similar Documents

Publication Publication Date Title
Austrian Prevention of pneumococcal infection by immunization with capsular polysaccharides of Streptococcus pneumoniae: current status of polyvalent vaccines
LU90809I2 (en) Vaccine comprising pneumococcal saccharides of serotypes 4,6b, 9v, 14,18c19f and 23f, each of them conjugated with a carrier protein crm 197
MY114786A (en) Vaccines
CA2460749A1 (en) Glycoconjugate vaccines for use in immune-compromised populations
RU93058676A (en) ORAL TREATMENT OF HELICOBACTERIAL INFECTION
ES8707861A1 (en) Immunogenic conjugates of E. coli LT-B enterotoxin subunit and capsular polymers.
BR0009166A (en) Vaccine
YU49068B (en) Procedure for obtaining pneumococcnic polysaccharide imunogenetic protein conjugate
IL145982A0 (en) Vaccines
NZ309713A (en) Oligosaccharides of S pneumoniae serotype 8 and their use in a vaccine
CA2145397A1 (en) Group b streptococcus type ii and type v polysaccharide-protein conjugate vaccines
KR970703164A (en) Treatment and Prevention of Helicobacter Infection (TREATMENT AND PREVENTION OF HELICOBACTER INFECTION)
ATE222930T1 (en) ANTIGENIC DRUG FOR TREATMENT OR PREVENTION
NZ337730A (en) use of an oligosaccharide hapten- carrier conjugate for immunizing against a bacterial or viral pathogen by administering
FI932759A0 (en) Enhancement of IL-4 For the purpose of vaccinia immunogenic generic immunoreaction
EP0603386A4 (en) Parenteral immunization against rotavirus.
NO913131L (en) IMMUNOGENIC CONJUGATES OF NON-TOXIC OLIGOSACCHARIDE FROM TABLE TELL PERTUSSIS LIPOOLYSACCHARIDE.
CA2133108A1 (en) Pasteurella haemolytica type a-1 bacterin-toxoid vaccine
AU4155700A (en) Use of fucosylated sialylated n-acetyl lactosamine carbohydrate structures for inhibition of bacterial adherence
EP0328390A3 (en) Peptide treatment of refractory infectious diseases
WO1996039113A3 (en) Oral administration of pneumococcal antigens
NO180234C (en) Immunogenic conjugate for the treatment of septic shock, compounds and covalent conjugate between D-glucosamine disaccharide and a carrier protein
ATA211388A (en) PREPARATIONS EFFECTIVE AGAINST PSEUDOMONAS AERUGINOSA INFECTIONS AND IMMUNO-LOBULING-PREDICATIONS, PREPARATIONS EFFECTIVE AGAINST PSEUDOMONAS AERUGINOSA BACTERIUM
Walther et al. Therapy of infections in immunocompromised patients with imipenem/cilastatin.
SE8104690L (en) VACCIN v KIKHOSTA